Two people can look at a mountain and see it differently

We have written quite a bit about protein degradation and molecular glues over the last two years, including sharing our findings, analysis and discussions with various company and academic expert interviews.

This time around it’s time to look at another biotech active in this space, albeit with completely different targets and approaches than what we have covered in detail previously.

We also look at what makes a great target from their perspective and how a deep understanding of certain elements may give them an advantage.

One of the beauties of this niche for me is not everyone is doing the exact same thing and there’s plenty of room for novel ideas to flourish and be investigated in both discovery and clinical phases.

So what’s unique about this company and why should you pay attention to what they are doing?

BSB subscribers can read more on our latest discussion around some novel early stage pipeline targets plus a company interview – you can log-in or click to access our latest content.

This content is restricted to subscribers

Posted by